Pioglitazone and alogliptin combination therapy in type 2 diabetes: A pathophysiologically sound treatment

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 671-690

  Triplitt, Curtis ^a   Cersosimo, Eugenio ^a   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Alogliptin; Diabetes; DPP 4 inhibitors; Incretins; Pioglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; CIMETIDINE; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NATEGLINIDE; NITRIC OXIDE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TROGLITAZONE; UNINDEXED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; URACIL;

ABDOMINAL PAIN; ADIPOSE TISSUE; AREA UNDER THE CURVE; ARTHRALGIA; ATHEROMA; ATHEROSCLEROSIS; BODY FAT; BODY FAT DISTRIBUTION; CARDIOVASCULAR EFFECT; CAROTID ARTERY; CAROTID INTIMA MEDIA THICKNESS; CHOLECYSTITIS; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAT WEIGHT GAIN; FATTY ACID BLOOD LEVEL; FLUID RETENTION; FOOD INTAKE; FOOT EDEMA; FRACTURE; GLUCAGON BLOOD LEVEL; GLUCOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLYCOGEN SYNTHESIS; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HEPATIC GLUCOSE PRODUCTION; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEG REVASCULARIZATION; LIPID LIVER LEVEL; LIPID METABOLISM; LUNG EMBOLISM; MONOTHERAPY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; POSTMENOPAUSE; PREGNANCY DIABETES MELLITUS; PRURITUS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DEFECT; STOMACH EMPTYING; STREPTOZOCIN DIABETES; STROKE; SUBCORNEAL PUSTULAR DERMATOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; ANIMAL; CARDIOVASCULAR SYSTEM; DRUG COMBINATION; DRUG EFFECT; GLUCOSE TOLERANCE TEST; LIVER; METABOLISM; MOUSE; PHYSIOLOGY; RAT;

ANIMALS; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MICE; PIPERIDINES; RATS; THIAZOLIDINEDIONES; URACIL;

EID: 79952062014     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Statistics Clearinghouse, NIH/NIDDK. Available from: diabetes.niddk.nih.gov. Accseesed on Apr 14, 2010.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
3. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascularand microvascular complications of Type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321: 405-412.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet. 1998;352: 854-865.
5. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355: 2427-2443.
6. Brown JB, Nichols GA, Perry A. The burden of treatment failure in Type 2 diabetes. Diabetes Care. 2004;27:1535-1340.
7. DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of Type 2 diabetes mellitus. Diabetes. 2009:58:773-795.
8. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137:2968-2978.
9. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: The glucagon, GIP, GLP-1, and GLP-2 receptors. Receptor Channels. 2002;8:179-188.
10. Gedulin B, Lawler R, Jodka C, Young A. Amylin inhibits pentagastrin-stimulated gastric acid secretion: Comparison with glucagon-like peptide-1 and exendin-4. Diabetes. 1997;46: Abstr 188.
11. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin. 2008;24:2943-2952.
12. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
13. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with Type 2 diabetes: A preliminary report. Diabetes Care. 2004;27:17-20.
14. Cheung BMY, Ong KL, Cherney SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999-2006. Am J Med. 2009;122:443-453.
15. DeFronzo RA. Pathogenesis of Type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes. Diabetes Reviews. 1997;5;177-269.
16. DeFronzo RA. Lilly lecture. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1998;37:667-687.
17. DeFronzo RA. Pathogenesis of Type 2 diabetes mellitus. Med Clin N Am. 2004;88:787-835.
18. Kahn SE. Clinical Review 135. The importance of beta-cell failure in the development and progression of Type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058.
19. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in Type 2 diabetes. Eur J Clin Invest. 2002;32:35-45.
20. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-DI. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes. 1998;37:1020-1104.
21. McGarry JD. Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of Type 2 diabetes. Diabetes. 2002;51:7-18.
22. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006:355:2297-2307.
23. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3-10.
24. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes. 2005;54: 1640-1648.
25. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630.
26. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of Type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89: 463-478.
27. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80:1037-1044.
28. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop Type 2 diabetes. Diabetes. 2003;52:2461-2474.
29. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: Results from the San Antonio Metabolism (SAM) study. Diabetologia. 2004;41: 31-39.
30. Diabetes Prevention Research Group: Reduction in the evidence of Type 2 diabetes with life-style intervention or metformin. N Engl J Med. 2002;346:393-403.
31. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of Type 2 diabetes by pharmacologicaltreatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
32. Buchanan TA, Xiang AH, Kjos SL, et al. Diabetes rates and B-cell function in the pioglitazone and prevention of diabetes (PIPOD) study. Diabetes. 2005;54 Suppl 1:A39.
33. DeFronzo RA, Banerji M, Bray GA, et al. Actos NOW for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009;9:17-25.
34. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week old db/db mice. Diabetologia. 2002;45: 1263-1273.
35. Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulin resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 2005;146:2069-2076.
36. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with Type 2 diabetes over 1 year. Diabetes Care. 2005;28:1936-1940.
37. Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidylpeptidase 4 inhibitor, on beta-cell function in patients with Type 2 diabetes,a model-based approach. Diabetes Obes Metab. 2008;10: 1212-1220.
38. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283:109-115.
39. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest. 1970;49:837-848.
40. Aguilar-Parada E, Eisentraut AM, Unger RH. Pancreatic glucagons secretion in normal and diabetic subjects. Am J Med Sci. 1969;257: 415-419.
41. Matsuda M, DeFronzo RA, Consoli A, Bressler P, Del Prato S. Doseresponse curve relation plasma glucagon to hepatic glucose production and glucose disposal in Type 2 diabetes mellitus. Metabolism. 2002; 51:1111-1119.
42. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in Type II diabetic patients. Diabetes Care. 1996;19:468-471.
43. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-2791.
44. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in Type 2 diabetic patients. Diabetes Obes Metab. 2008;10: 1204-1211.
45. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with Type 2 diabetes: A randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167-174.
46. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in Type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292: E871-E883.
47. Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects ofpioglitazone and/or simvastatin in high cardiovascular-risk patients with elevated high sensitivity c-reactive protein: The PIOSTAT study. J Am Coll Cardiol. 2007;49:290-297.
48. Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in Type 2 diabetes patients improves vascular dysfunction by different mechanisms. Diabetes Care. 2008;31:121-127.
49. Wajcberg E, Sriwijitkamol A, Musi N, DeFronzo RA, Cersosimo E. Relationship between vascular reactivity and lipids in Mexican-Americans with Type 2 diabetes treated with pioglitazone. J Clin Endocrinol Metab. 2007;92:1256-1262.
50. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-1554.
51. Lloyd-Jones DM, Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med. 1996;47:365-375.
52. de Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokineinduced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
53. Defronzo RA. Insulin resistance, lipotoxicity, Type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-1287.
54. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated Type 2 diabetic patients. Int J Obes. 2004;28:783-789.
55. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in liver and muscle in Type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24: 710-719.
56. Gastaldelli A, Miyazaki Y, Mahankali A, et al. The effect of pioglitazone on the liver. Diabetes Care. 2006;29:2275-2281.
57. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in Type 2 diabetes patients. Am J Physiol Endocrinol Metab. 2007;292: E871-E883.
58. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing theeffect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097-2104.
59. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
60. Singh S, Loke UK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. JAMA. 2007;298:1189-1195.
61. Miyazaki Y, Matsuda M, Defronzo RA. Dose-response effect of pioglitazoneon insulin sensitivity and insulin secretionin Type 2 diabetes. Diabetes Care. 2002;25:517-523.
62. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-286.
63. The Dream (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet. 2006;368:1096-1105.
64. Bunck MC, Diamont M, Corner A, et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated Type 2 diabetic patients: A randomized, controlled trial. Diabetes Care. 2009;32:762-768.
65. DeFronzo RA, Banerji MA, Bray GA, et al; for the ACT NOW Study Group. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW). Diabetologia. 2010;53:435-445.
66. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: Results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55:1430-1435.
67. Nissen SE, Nicholls SJ, Wolski K; PERISCOPE Investigators. Comparisonof pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA. 2008;299:1561-1573.
68. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: A randomized trial. JAMA. 2006;296:2572-2581.
69. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with Type 2 diabetes. Diabetologia. 2005;48:1093-1104.
70. Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in Type 2 diabetes mellitus: A 42-month, open-label, observational, primary care study. Curr Med Res Opin. 2006;22:1211-1215.
71. Tan MH, Baksi A, et al; GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with Type 2 diabetes. Diabetes Care. 2005;28:544-550.
72. Rosenstock J, Goldstein BJ, Vinik A; RESULT Study Group. Effect of early addition of rosiglitazone to sulphonylurea therapy in older Type 2 diabetes patients (60 years): The Rosiglitazone Early vs SULphonylurea Titration (RESULT) study. Diab Obes Metab. 2006;8:49-57.
73. Home PD, Jones NP, Pocock SJ, et al. RECORD Study Group. Rosiglitazone RECORD study: Glucose control outcomes at 18 months. Diabet Med. 2007;24:626-634.
74. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in Type 2 diabetic patients. Diabetes Obes Metab. 2008;10: 1204-1211.
75. Rosmarakis ES, Falagas ME. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: A meta-analysis of randomized controlled trials. Am Heart J. 2007;154:144-150.
76. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA. 2007;12;298:1180-1188.
77. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the proactive study (PROspective pioglitAzone Clincal Trial In macroVascular Events): A randomized controlled trial. Lancet. 2005;366:1279-1289.
78. Miyazaki Y, Glass L, Triplitt C, et al. Abdominal fat distribution and peripheral and hepatic insulin resistance in Type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;46:E1135-1481, E1143.
79. Petersen KF, Dufour S, Shulman GI. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulinresistant offspring of Type 2 diabetic parents. PLoS Medicine. 2005;2:879-884.
80. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and the American Diabetes Association: Oct 7, 2003. Circulation. 2003;108:2941-2948.
81. Kaul S, Bolger A, Herrington D, Giugliano R, Eckel R. Thiazolidinedionedrugs and cardiovascular risks: A science advisory from the American Heart Association and American College of CardiologyFoundation. Circulation. 2010;121:1868-1877.
82. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure; an observational study. Circulation. 2005;111:583-590.
83. Puschett JB. Pharmacological classification and renal actions of diuretics. Cardiology. 1994;84 Suppl 2:4-13.
84. Karalliedde J, Buckingham R, Starkie M, et al. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol. 2006;17:3482-3490.
85. Valentine WJ, Bottomley JM, Palmer AJ, et al; PROactive Study Group. PROactive 06: Cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med. 2007;24:982-1002.
86. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52.
87. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004;47:357-366.
88. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: The neglected incretin revisited. Regul Pept. 2002;107: 1-13.
89. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in Type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-3723.
90. Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47:159-169.
91. Jones IR, Owens DR, Luzio S, Williams S, Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32: 668-677.
92. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide-1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with Type-2 diabetes mellitus. J Clin Invest. 1993;91:301-307.
93. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet. 2006;368:1696-1705.
94. Deacon CF. Incretin-based treatment of Type 2 diabetes: Glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2007;9 Suppl 1:23-31.
95. Ferrannini E, Bjorkman O, Reichard GA, Pilo A, Olson M. The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes. 1985;34:580-588.
96. Ahren B. Gut peptides and Type 2 diabetes mellitus treatment. Curr Diab Rep. 2003;3:365-372.
97. Ahren B. Insulinotropic action of truncated glucagon-like peptide-1 in mice. Acta Physiol Scand. 1995;153:205-206.
98. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagonlike peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987; 84:3434.
99. Kashima Y, Miki T, Shibasaki T, et al. Critical role of cAMP-GEFII - Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem. 2001;276:46046-46053.
100. Fehmann HC, Goke R, Goke B. Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin. Mol Cell Endocrinol. 1992;85: C39-C44.
101. Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. 1995;136: 4910-4917.
102. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide- I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992;130:159-166.
103. Fehmann HC, Habener JF. Galanin inhibits proinsulin gene expression stimulated by the insulinotropic hormone glucagon-like peptide-I(7-37) in mouse insulinoma beta TC-1 cells. Endocrinology. 1992;130:2890-2896.
104. Drucker DJ. Glucagon-like peptides: Regulators of cell proliferation,differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-171.
105. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283:109-115.
106. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest. 1970;49:837-848.
107. Aguilar-Parada E, Eisentraut AM, Unger RH. Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci. 1969;257: 415-419.
108. Larsson H, Berglund G, Ahren B. Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab. 1995;80:1778-1782.
109. Ahren B, Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia. 2001;44:1998-2003.
110. Larsson H, Ahren B. Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: Outcome of a prospective study in postmenopausal Caucasian women. Diabetologia. 2000;43: 194-202.
111. Unger RH. Glucagon physiology and pathophysiology. N Engl J Med. 1971;285:443-449.
112. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes. 1997;46:785-791.
113. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with Type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3082-3089.
114. Horowitz M, Dent J, Fraser R, Sun W, Hebbard G. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci. 1994; 39 Suppl 12:7S-13S.
115. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying of an oral glucose solution in Type 2 diabetic patients. J Nucl Med. 1992;33:1496-1500.
116. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia. 1994;37:543-551.
117. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in Type II diabetic patients. Diabetes Care. 1996;19:468-471.
118. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia. 1993;36:857-862.
119. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying of an oral glucose solution in Type 2 diabetic patients. J Nucl Med. 1992;33:1496-500.
120. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with Type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62:173-181.
121. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273: G920-G927.
122. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 1996;45: 832-835.
123. Tang-Christensen M, Larsen PJ, Goke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:R848-R856.
124. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69-72.
125. Ahren B. Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes. Bioessays. 1998;20: 642-651.
126. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86:4382-4389.
127. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjects. Diabetes. 1995;44: 1126-1131.
128. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50:2297-2300.
129. Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, Odaka H. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009:85:122-126.
130. Moritoh Y, Takeuchi K, Asakawa T, Kataoka, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008;588:325-332.
131. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in health male subjects. Clin Ther. 2008:30:513-527.
132. ® [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2009.
133. ® [package insert]. Whitehouse Station, NJ: Merck and Company, Inc., 2010
134. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability prof iles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind placebocontrolled multiple-dose study in adult patients with Type 2 diabetes. Clin Ther. 2008;30:499-512.
135. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes and inadequate glycemic control. Diabetes Care. 2008;31:2315-2317.
136. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11:167-176.
137. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: A multicenter, randomized, doubleblind, placebo-controlled study. Int J Clin Pract. 2009;63:46-55.
138. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Aloglitpin added to insulin therapy in patients with Type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11:1145-1152.
139. Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: A two-phase, crossover study in health subjects. Int J Clin Pharmacol Ther. 2010;48:46-58.
140. Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: Pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009;49:1210-1219.
141. Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with Type 2 diabetes: A randomized, double-blind, placebocontrolled study. Curr Med Res Opin. 2009;25:2361-2371.
142. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Effect of alogliptin combined with pioglitazone in glycemic controlin metformin-treated patients with Type 2 diabetes. Diabetes. 2009; 58 Suppl 1:A519, Abstr 2023.
143. Defronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Effect of alogliptin combined with pioglitazone on glycemic control in metformin-treated patients with Type 2 diabetes. Diabetes. 2009; 58 Suppl 1:A519-A520, Abstr 2024.
144. Rosenstock J, Inzucchi S, Seufert J, Fleck P, Wilson C, Mekki Q. Efficacy and safety of alogliptin combined with pioglitazone in patientswith Type 2 diabetes inadequately controlled with diet and exercise. Diabetes. 2009;58 Suppl 1:A523, Abstr 2036.
145. Inzucchi SE, Rosenstock J, Seufert J, Fleck P, Wilson C, Mekki Q. Effect of combination therapy with alogliptin and pioglitazone in drug-naïve patients with Type 2 diabetes on b-cell function and insulin resistance. Diabetes. 2009;58 Suppl 1:A520, Abstr 2026.